Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. (Ahmed N, Ali A, Kim S, Oloyede T, Bye M, Gowda L, Kamble RT, Mirza AS, Nadiminti KV, Pophali PA, Rodriguez-Bonilla C, Sieg A, Strouse C, Abid MB, Afrough A, Aljurf M, Beitinjaneh AM, Chhabra S, Choe M, Hilal T, Iqbal M, Jain T, Kharfan-Dabaja MA, Modi D, Orti G, Pawarode A, Rao U, Riedell PA, Saad A, Seo S, Balari AS, Wagner JL, Wudhikarn K, Turtle CJ, Phillips CL, Pasquini MC, Ahmed S, Ganguly S, Moskop A) Transplant Cell Ther 2026 Jun 24 PMID: 42341926 06/25/2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. (Mirza AS, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid MB, Afrough A, Ahmed S, Badar T, Barba P, Bhatt VR, Brown VI, Dahiya S, Deol A, Epperla N, Ganguly S, Grover NS, Hashmi H, Hashmi S, Hematti P, Hildebrandt GC, Hill JM Jr, Hossain NM, Ibrahim U, Johnson PC, Kharfan-Dabaja MA, Krem MM, Lekakis LJ, Maziarz RT, Murthy HS, Riedell PA, Salas MQ, Shouse G, Strouse C, Thakar MS, Turtle CJ, Woolfrey A, Wudhikarn K, Yared JA, Pasquini MC, Gowda L) Blood Neoplasia 2026 May;3(2):100187 PMID: 41867486 PMCID: PMC12999346 SCOPUS ID: 2-s2.0-105034581604 03/23/2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. (Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning M, Egini O, Odstrcil Bobillo MS, Kallam A, Thiruvengadam SK, Lee DC, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I) Blood 2026 Jul 16;148(3):348-360 PMID: 41774517 SCOPUS ID: 2-s2.0-105041226033 03/03/2026 2 Citations
Rforce: Random Forests for Composite Endpoints. (Wang Y, Kim S, Lin CW, Ahn KW) Stat Med 2026 Feb;45(3-5):e70413 PMID: 41640374 PMCID: PMC12973044 SCOPUS ID: 2-s2.0-105029504686 02/05/2026
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. (Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumari PR, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror M) Blood Adv 2026 Jan 13;10(1):217-227 PMID: 40811818 PMCID: PMC12811452 SCOPUS ID: 2-s2.0-105027158017 08/14/2025 5 Citations
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. (Ahmed N, Thiruvengadam SK, Hamadani M, Hu ZH, Grover N, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang M, Kim S, Bye M, Kharfan-Dabaja MA, Sauter C, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan B, Nunes A, Dalton D, Kloos I, Lee D, Xu H, Pasquini MC, Herrera AF) Blood Adv 2025 Oct 28;9(20):5382-5396 PMID: 40706035 PMCID: PMC12597645 SCOPUS ID: 2-s2.0-105022684848 07/24/2025 19 Citations
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. (Jain T, Estrada-Merly N, Salas MQ, Kim S, DeVos J, Chen M, Fang X, Kumar R, Andrade-Campos M, Elmariah H, Agrawal V, Aljurf M, Bacher U, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Bhatt VR, Bredeson C, DeFilipp Z, Dholaria B, Farhadfar N, Farhan S, Gandhi AP, Ganguly S, Gergis U, Grunwald MR, Hamad N, Hamilton BK, Inamoto Y, Iqbal M, Jamy O, Juckett M, Kharfan-Dabaja MA, Krem MM, Lad DP, Liesveld J, Al Malki MM, Malone AK, Murthy HS, Ortí G, Patel SS, Pawarode A, Perales MA, van der Poel M, Ringden O, Rizzieri DA, Rovó A, Savani BN, Savoie ML, Seo S, Solh M, Ustun C, Verdonck LF, Wingard JR, Wirk B, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott B, Saber W, Gupta V) Blood Adv 2024 Aug 27;8(16):4281-4293 PMID: 38916866 PMCID: PMC11372592 SCOPUS ID: 2-s2.0-85203078773 06/25/2024 12 Citations
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. (Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W) Haematologica 2023 Jul 01;108(7):1900-1908 PMID: 36779595 PMCID: PMC10316233 SCOPUS ID: 2-s2.0-85152676494 02/14/2023 28 Citations
Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities. (Olson TS, Frost BF, Duke JL, Dribus M, Xie HM, Prudowsky ZD, Furutani E, Gudera J, Shah YB, Ferriola D, Dinou A, Pagkrati I, Kim S, Xu Y, He M, Zheng S, Nijim S, Lin P, Xu C, Nakano TA, Oved JH, Carreno BM, Bolon YT, Gadalla SM, Marsh SG, Paczesny S, Lee SJ, Monos DS, Shimamura A, Bertuch AA, Gragert L, Spellman SR, Babushok DV) JCI Insight 2022 Nov 22;7(22) PMID: 36219480 PMCID: PMC9746824 SCOPUS ID: 2-s2.0-85143530400 10/12/2022 24 Citations
Comparison of outcomes of HCT in blast phase of BCR-ABL12 MPN with de novo AML and with AML following MDS (Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W) Blood Advances 13 October 2020;4(19):4748-4757 SCOPUS ID: 2-s2.0-85092401454 10/13/2020 19 Citations
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. (Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W) Blood Adv 2020 Oct 13;4(19):4748-4757 PMID: 33007075 PMCID: PMC7556156 SCOPUS ID: 2-s2.0-85092401454 10/03/2020 19 Citations
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. (Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS) Blood Adv 2020 Mar 24;4(6):983-992 PMID: 32168378 PMCID: PMC7094022 SCOPUS ID: 2-s2.0-85082533373 03/14/2020 49 Citations
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. (Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredeson C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugrue M, Warkentin P, Wingard JR) Biol Blood Marrow Transplant 2020 Jun;26(6):1210-1217 PMID: 32088366 PMCID: PMC7347029 SCOPUS ID: 2-s2.0-85082823451 02/24/2020 8 Citations
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M) Blood Adv 2019 Oct 22;3(20):3123-3131 PMID: 31648332 PMCID: PMC6849938 SCOPUS ID: 2-s2.0-85075150491 10/28/2019 56 Citations